The core of Seer's business revolves around its Proteograph Product Suite, an integrated solution designed to enable deep, unbiased proteomics research. This segment encompasses the development, manufacturing, and commercialization of consumables, automation instrumentation, and software. The Proteograph platform utilizes proprietary engineered nanoparticles (NPs) to analyze proteins, offering high-throughput and high-resolution proteomic analysis. Research and development activities focus on improving the sensitivity, specificity, and scalability of the platform. The technology is applied in various therapeutic areas, including oncology, neurology, and immunology, to identify biomarkers, understand disease mechanisms, and accelerate drug discovery. The platform's ability to provide deep proteomic insights at scale gives Seer a competitive advantage in the market. Future opportunities include expanding the platform's applications, entering new markets, and forming strategic partnerships to enhance its reach and impact. Regulatory and clinical aspects are crucial for applications in diagnostics and clinical trials, requiring rigorous validation and adherence to regulatory standards. Partnerships with companies like Thermo Fisher Scientific are key to expanding market access and accelerating adoption.

Seer provides research and development services to academic institutions, life sciences and research laboratories, and biopharmaceutical and biotechnology companies. This segment focuses on utilizing the Proteograph Product Suite to conduct proteomic studies for various research purposes, including therapeutic and diagnostic research, and clinical trials. R&D activities involve collaborative projects with partners like Discovery Life Sciences, LLC and the Salk Institute for Biological Studies, aimed at advancing proteomic research and identifying novel biomarkers. The company leverages its proprietary engineered nanoparticles and advanced instrumentation to provide deep proteomic insights. The services are applicable across multiple therapeutic areas, including oncology, neurology, and immunology, with the goal of improving patient outcomes through precision medicine and targeted therapies. Market positioning is based on providing high-quality, unbiased proteomic data to accelerate research and development efforts. Future opportunities include expanding the service offerings, entering new markets, and forming strategic partnerships to enhance its reach and impact. Regulatory and clinical aspects are crucial for applications in diagnostics and clinical trials, requiring rigorous validation and adherence to regulatory standards.